WO2002000262A3 - Modulation of chromosome function by chromatin remodeling agents - Google Patents

Modulation of chromosome function by chromatin remodeling agents Download PDF

Info

Publication number
WO2002000262A3
WO2002000262A3 PCT/EP2001/008097 EP0108097W WO0200262A3 WO 2002000262 A3 WO2002000262 A3 WO 2002000262A3 EP 0108097 W EP0108097 W EP 0108097W WO 0200262 A3 WO0200262 A3 WO 0200262A3
Authority
WO
WIPO (PCT)
Prior art keywords
cre
chromatin remodeling
modulation
chromatin
contacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/008097
Other languages
French (fr)
Other versions
WO2002000262A2 (en
Inventor
Ulrich Laemmli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Geneva filed Critical University of Geneva
Priority to JP2002505043A priority Critical patent/JP2004501620A/en
Priority to AU2001279744A priority patent/AU2001279744A1/en
Priority to EP01957960A priority patent/EP1294406A2/en
Priority to CA002409408A priority patent/CA2409408A1/en
Publication of WO2002000262A2 publication Critical patent/WO2002000262A2/en
Publication of WO2002000262A3 publication Critical patent/WO2002000262A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)

Abstract

The present invention concerns a process for modulating the function of a DNA element in a eukaryotic cell, comprising the step of contacting a genomic DNA element, so-called 'chromatin responsive element' (CRE), with a compound having a molecular weight of less than approximately 5 KDa, and having the capacity to bind a sequence-specific manner to said CRE, said step of contacting being carried out in conditions permitting chromatin remodeling of the CRE by said compound, wherein said chromatin remodeling of the CRE alters the activity of one or more other DNA elements, so called 'modulated DNA elements' in the genome.
PCT/EP2001/008097 2000-06-26 2001-06-26 Modulation of chromosome function by chromatin remodeling agents Ceased WO2002000262A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002505043A JP2004501620A (en) 2000-06-26 2001-06-26 Regulation of chromosomal function by chromatin remodeling substances
AU2001279744A AU2001279744A1 (en) 2000-06-26 2001-06-26 Modulation of chromosome function by chromatin remodeling agents
EP01957960A EP1294406A2 (en) 2000-06-26 2001-06-26 Modulation of chromosome function by chromatin remodeling agents
CA002409408A CA2409408A1 (en) 2000-06-26 2001-06-26 Modulation of chromosome function by chromatin remodeling agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60364700A 2000-06-26 2000-06-26
US09/603,647 2000-06-26

Publications (2)

Publication Number Publication Date
WO2002000262A2 WO2002000262A2 (en) 2002-01-03
WO2002000262A3 true WO2002000262A3 (en) 2002-10-31

Family

ID=24416340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008097 Ceased WO2002000262A2 (en) 2000-06-26 2001-06-26 Modulation of chromosome function by chromatin remodeling agents

Country Status (5)

Country Link
EP (1) EP1294406A2 (en)
JP (1) JP2004501620A (en)
AU (1) AU2001279744A1 (en)
CA (1) CA2409408A1 (en)
WO (1) WO2002000262A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669562B2 (en) 2003-10-24 2020-06-02 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of MAR sequences

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282070A1 (en) * 2000-07-11 2002-01-21 Universite De Geneve Linked, sequence-specific DNA-binding molecules
DK1395669T3 (en) 2001-01-26 2009-11-16 Selexis Sa Matrix binding regions and methods for using them
JP2021165233A (en) * 2018-05-28 2021-10-14 国立大学法人京都大学 Pharmaceutical compositions and RUNX inhibitors targeting RUNX binding sequences

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
WO2002004476A2 (en) * 2000-07-11 2002-01-17 Universite De Geneve Linked, sequence-specific dna-binding molecules
WO2002034295A1 (en) * 2000-10-27 2002-05-02 Memorial Sloan-Kettering Cancer Center Synthetic regulatory compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143901A (en) * 1996-07-31 2000-11-07 Genesoft, Inc. Complex formation between dsDNA and pyrrole imidazole polyamides
WO2002004476A2 (en) * 2000-07-11 2002-01-17 Universite De Geneve Linked, sequence-specific dna-binding molecules
WO2002034295A1 (en) * 2000-10-27 2002-05-02 Memorial Sloan-Kettering Cancer Center Synthetic regulatory compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAGGA R ET AL: "HMG I /Y regulates long-range enhancer-dependent transcription on DNA and chromatin by changes in DNA topology.", NUCLEIC ACIDS RESEARCH, (2000 JUL 1) 28 (13) 2541-50., XP002209472 *
BAILLY C ET AL: "SEQUENCE-SPECIFIC DNA MINOR GROOVE BINDERS. DESIGN AND SYNTHESIS OF NETROPSIN AND DISTAMYCIN ANALOGUES", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 9, no. 5, 1 September 1998 (1998-09-01), pages 513 - 538, XP000619990, ISSN: 1043-1802 *
DICKINSON LILIANE A ET AL: "Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 22, 27 October 1998 (1998-10-27), Oct. 27, 1998, pages 12890 - 12895, XP002209473, ISSN: 0027-8424 *
JANSSEN S ET AL: "Chromatin opening of DNA satellites by targeted sequence-specific drugs.", MOLECULAR CELL. UNITED STATES NOV 2000, vol. 6, no. 5, November 2000 (2000-11-01), pages 999 - 1011, XP002209475, ISSN: 1097-2765 *
JANSSEN S ET AL: "Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster.", MOLECULAR CELL. UNITED STATES NOV 2000, vol. 6, no. 5, November 2000 (2000-11-01), pages 1013 - 1024, XP002209474, ISSN: 1097-2765 *
MAESHIMA KAZUHIRO ET AL: "Specific targeting of insect and vertebrate telomeres with pyrrole and imidazole polyamides.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 12, 15 June 2001 (2001-06-15), pages 3218 - 3228, XP002209490, ISSN: 0261-4189 *
See also references of EP1294406A2 *
SUROVAYA A N ET AL: "Hairpin polyamides that use parallel and antiparallel side-by-side peptide motifs in binding to DNA.", JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS. UNITED STATES APR 1997, vol. 14, no. 5, April 1997 (1997-04-01), pages 595 - 606, XP000749591, ISSN: 0739-1102 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10669562B2 (en) 2003-10-24 2020-06-02 Selexis S.A. High efficiency gene transfer and expression in mammalian cells by a multiple transfection procedure of MAR sequences

Also Published As

Publication number Publication date
WO2002000262A2 (en) 2002-01-03
EP1294406A2 (en) 2003-03-26
CA2409408A1 (en) 2002-01-03
AU2001279744A1 (en) 2002-01-08
JP2004501620A (en) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004042029A3 (en) Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2002004488A3 (en) Nucleic acid binding polypeptides
AU1491401A (en) Improving dideoxynucleotide-triphosphate utilization by the hyper-thermophilic dna polymerase from the archaeon pyrococcus furiosus
DE69929524D1 (en) OLIGONUCLEOTIDES WITH SPECIFIC CHIRALS FOR BINDING TAPES PHOSPHOROTHIOATINOLUCLEOSIDE BINDINGS
CA2391591A1 (en) Permanent amniocyte cell line, the production thereof and its use for producing gene transfer vectors
WO2001018248A3 (en) Quorum sensing signaling in bacteria
HUP9701341A3 (en) Modified thermostable dns polymerase, process for producing thereof, nucleic acid codind the enzyme, vector containing the nucleic acid, a composition containing thereof
ATE239090T1 (en) METHOD FOR GENERATING SINGLE STRANDED DNA MOLECULES
WO2001051621A3 (en) Dna polymerase mutant having one or more mutations in the active site
WO1999057325A3 (en) Enzymes mixture
WO2001019800A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
JP2002505071A5 (en)
DE59709707D1 (en) VEHICLE FOR TRANSPORTING MOLECULAR SUBSTANCE
WO2000046402A8 (en) Genomic analysis method
WO2003100074A3 (en) Animal genotyping method
WO2002044378A3 (en) Wnt signalling assay, methods and uses thereof
WO2002036814A3 (en) Diagnosis of diseases associated with cdk4 by determining the methylation state of the cdk4
WO2002012554A3 (en) Diagnosis of diseases which are associated with cd24
AU2214799A (en) Nucleic acid markers for apospory-specific genomic region
WO1998051791A1 (en) Gene causative of rheumatoid arthritis, method for the diagnosis of rheumatoid arthritis, and method for the determination of factors causing rheumatoid arthritis
AU2001256232A1 (en) Genes isolated from dendritic cells, gene products and methods employing the same
WO2002006294A3 (en) Haplotypes of the mmp13 gene
WO2001006001A3 (en) Dna for detecting changes in chromosome 8
WO1999064562A3 (en) Expression control elements from genes encoding starch branching enzymes
WO1997038082A3 (en) Hypertonia gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001957960

Country of ref document: EP

Ref document number: 2409408

Country of ref document: CA

Ref document number: 2001279744

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2002 505043

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2001957960

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001957960

Country of ref document: EP